retatrutide study results 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A in those with concurrent obesity and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Retatrutide Shows Promising Results in

As a control group, pwIIH electing for UCWM only were matched for age-, sex- and BMI in a 1:2 ratio

An LDI Fellow and Chronic Pain Researcher Call on Health Plans To Lower Barriers to Physical Therapy, Acupuncture, and Interdisciplinary Pain Care Chart of the Day: Researchers Urge Easier Renewals and Better Support To Prevent Gaps in Care While They Wait for Medicare, People Approved for Social Security Disability Die at Higher Rates Compared to the General Public

If protein has been hard to hit on a suppressed appetite, our guide to hitting your protein goals on GLP-1s has practical strategies that work even when you're not very hungry

doi:10.1111/j.2040-1124.2010.00022.x

It helps reduce body weight by promoting feelings of satiety and fullness, leading to decreased calorie intake

JCL roundtable